A Randomized, Double-Blind, Phase IV Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients

Trial Profile

A Randomized, Double-Blind, Phase IV Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Atenolol (Primary) ; Fimasartan (Primary)
  • Indications Essential hypertension
  • Focus Biomarker; Therapeutic Use
  • Sponsors Boryung Pharmaceutical
  • Most Recent Events

    • 21 Sep 2016 Status changed from recruiting to completed.
    • 31 Aug 2015 Planned primary completion date changed from 1 Nov 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 07 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top